Joshua Reed

Joshua Reed (finance chief) discloses dealings in 3 companies, chiefly Scholar Rock Holding Corp, Aldeyra Therapeutics, Inc. and Alkermes plc. We count 13 filings; the first trade dates from 5 March 2019 and the latest from 8 October 2026.

Both buying and selling appear: 1 purchase worth €14k, against 4 sales worth €285k. Netting one side against the other leaves €272k of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 7 share grants and 1 option exercise. In 2026 alone, the filings show no purchases and 2 sales.

Most recently, on 9 October 2026, the filings show an option exercise in Alkermes plc. The most recent open-market purchase was published on 9 September 2019, 2,601 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.